Arcutis Biotherapeutics (ARQT) is back on investor radars after second quarter 2026 results showed revenue of $129.86 million, net income of $15.01 million, and raised full year net product sales guidance.

The latest results and raised full year guidance have come alongside a 19.07% 3 month share price return and a 71.23% 1 year total shareholder return. However, shorter term share price returns over the past month and year to date have moved lower, suggesting momentum has cooled after a strong run.

If Arcutis Biotherapeutics has caught your attention after this earnings move, it can be useful to see what else is happening in healthcare and biotech. You can scan for other dermatology and treatment focused opportunities through our 43 healthcare AI stocks

After Arcutis Biotherapeutics moved from loss to profit and raised its 2026 sales guidance, the share price has cooled in recent weeks. Does the current valuation still leave enough potential upside to justify taking on the risk?

Most Popular Narrative: 31.4% Undervalued

Compared to Arcutis Biotherapeutics' last close at $25.29, the most followed narrative sees fair value at $36.88, implying a sizeable valuation gap that rests on specific growth and profitability assumptions.

Arcutis is poised to sustain and accelerate top-line revenue growth through continued expansion of ZORYVE indications, targeting large, underserved populations such as pediatric atopic dermatitis and scalp psoriasis, while leveraging broadening insurance coverage and the ongoing shift away from steroid use in chronic dermatologic conditions.

Want to understand why this narrative supports a higher fair value for Arcutis Biotherapeutics? It hinges on stacked assumptions around revenue expansion, rising margins, and a richer earnings profile in the next few years. The full story connects those building blocks into one valuation case.

Result: Fair Value of $36.88 (UNDERVALUED)

However, Arcutis Biotherapeutics still faces meaningful risks, including its heavy reliance on ZORYVE and ongoing payer or reimbursement uncertainty that could affect future revenue and margins.

Another View: What Multiples Say About Arcutis Biotherapeutics

The analyst narrative and fair value of $36.88 present Arcutis Biotherapeutics as 31.4% undervalued. However, the current P/E of 111.5x is far above both the US Biotechs industry at 17.2x and an estimated fair ratio of 39.1x. That gap points to real valuation risk if expectations ease.

For a closer look at how these earnings multiples stack up and what they imply for risk and potential reward, review the valuation breakdown next See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Arcutis Biotherapeutics mixed between valuation upside and clear risks, it makes sense to move quickly and review the details yourself. To see what investors view as the key positives today, start with the 4 key rewards.

Looking for more investment ideas beyond Arcutis Biotherapeutics?

If Arcutis Biotherapeutics has sharpened your focus on where to put fresh capital, do not stop here. Broaden your watchlist with targeted stock ideas that match your goals.

• Target a shortlist of companies that combine quality and attractive pricing by reviewing the 52 high quality undervalued stocks before the crowd catches up.
• Strengthen your portfolio’s foundation with the solid balance sheet and fundamentals stocks screener (48 results) so you are not relying on companies with fragile finances when conditions change.
• Identify potential future standouts by scanning the screener containing 21 high quality undiscovered gems and looking for strong fundamentals before they become widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.